A5013399740- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Colorectal Cancer Treatments and Studies
- Gut microbiota and health
- Single-cell and spatial transcriptomics
- Cancer Genomics and Diagnostics
- Allergic Rhinitis and Sensitization
- Sarcoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Mycobacterium research and diagnosis
- Brain Metastases and Treatment
- Retinal and Macular Surgery
- Protein Degradation and Inhibitors
- Pediatric health and respiratory diseases
- Cancer, Stress, Anesthesia, and Immune Response
- Immune cells in cancer
- Herbal Medicine Research Studies
- Cutaneous Melanoma Detection and Management
- Cancer Diagnosis and Treatment
- Ocular Oncology and Treatments
- CRISPR and Genetic Engineering
The Christie NHS Foundation Trust
2016-2024
Health Sciences Centre
2022
Abstract The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on specific characteristics linked benefits ICIs. We performed shotgun metagenomic sequencing stool samples collected before ICI initiation from five observational cohorts recruiting ICI-naive patients advanced cutaneous melanoma ( n = 165). Integrating dataset 147 previously published studies, we found that a relevant,...
Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival anti-programmed cell death protein 1 (anti-PD-1) monotherapy or combination with anticytotoxic T-cell lymphocyte-4 (ipilimumab [IPI]; anti-PD-1 ± IPI) by including routine clinical data available at the point of treatment initiation.One thousand six hundred forty-four patients melanoma treated IPI 16 centers from...
Abstract Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve success of these interventions, understanding changes during ICB is urgently needed. Here through longitudinal profiling 175 patients treated with advanced melanoma, we show that several microbial species-level genome bins (SGBs) and pathways exhibit distinct patterns from baseline in achieving progression-free survival (PFS) 12...
10005 Background: PD1 induces long-term responses in approximately 30% of MM pts, however 2/3 are resistant (innate or acquired) and will require further treatment. A subset these pts benefit from IPI IPI+PD1, but yet to be identified. We sought determine; i) response rate (RR) survival IPI+/-PD1 after progression, ii) clinical predictors IPI+/-PD1. Methods: then treated with were studied. Demographics, disease characteristics baseline blood parameters examined. Univariate, multivariate...
To assess efficacy and toxicity of combination immunotherapy with ipilimumab plus nivolumab in routine practice a retrospective multicentre cohort patients advanced melanoma.This analysis included melanoma treated between October 2015 January 2020 at six centres Australia, Europe the United States America. We describe outcomes (overall survival [OS], progression-free [PFS] objective response rate [ORR]) treatment-naïve pre-treated patients, without brain metastases, treatment-related adverse...
e14684 Background: Immune checkpoint inhibitors (ICIs) allow the immune system to target cancer cells. The is affected by seasonal factors e.g. viruses, allergens, vaccines and ultraviolet exposure. There evidence that some immune-related adverse events are more common in winter higher vitamin D (VD) levels VD supplementation associated with longer overall survival (OS). This study aimed determine if season of ICI initiation was OS. Methods: We evaluated patients who received treatment at...
Abstract Recent advances in targeted and immunotherapies have unlocked potent treatment options for malignant melanoma patients. However, therapies are associated with limited response durations only a fraction of patients benefit from immunotherapies. The analysis circulating tumour DNA (ctDNA) provides powerful tool the continuous assessment responses We established robust pipeline serial, prospective ctDNA By combining next generation sequencing (NGS)- droplet digital PCR (ddPCR)-based...
Abstract Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve success of these interventions, understanding dynamics during ICB is urgently needed. Through longitudinal shotgun metagenomics profiling in 175 patients treated with advanced melanoma, we show that microbial species-level genome bins (SGBs; an improved species-delineation) and pathways exhibit contrasting patterns from baseline...
Purpose: To assess efficacy and toxicity of combination immunotherapy with ipilimumab plus nivolumab in routine practice a retrospective multicentre cohort patients advanced melanoma.Patients Methods: This analysis included melanoma treated between October 2015 January 2020 at 6 centres Australia, Europe USA. We describe outcomes (overall survival [OS], progression-free [PFS] objective response rate [ORR]) treatment-naïve pre-treated patients, without brain metastases, treatment-related...
6586 Background: The prevalence of immune-mediated toxicities from immune checkpoint inhibitors (ICIs) is well described. However, the characteristics and treatment patterns for patients with emergency presentations due to toxicity are less known. Methods: This study all in treated ICIs was performed at Christie NHS Foundation Trust, Manchester, United Kingdom May 2018-February 2020. aims were describe patient those diagnosed an toxicity. Results: In total, 597 receiving had presentation...